title: Drug design using the example of the complement system inhibitors' development.
abstract: Undesired activation of the complement system, a part of the immune system, is a major pathogenic factor contributing to various diseases, such as ischemia-reperfusion injury, sepsis, asthma, allergic reactions, rheumatoid arthritis, Alzheimer's disease, myasthenia, multiple sclerosis and others. The history of the development of complement system inhibitors, preventing its destructive action on the body, represents the evolution of the main methods of drug design. This review illustrates the main approaches of drug design, ranging from screening and modification of natural products to structure-based ligand design, on the basis of complement inhibitors' creation. The current status of the field of complement inhibitors is also discussed.
authors.affiliation: M.V. Lomonosov State Academy of Fine Chemical Technology, Department of Biotechnology, Pr. Vernadskogo 86, 119571 Moscow, Russia. sveta407@mail.ru
authors.forename: Svetlana
authors.initials: S
authors.lastname: Bureeva
authors.forename: Julian
authors.initials: J
authors.lastname: Andia-Pravdivy
authors.forename: Alexander
authors.initials: A
authors.lastname: Kaplun
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D001685:Biological Factors / Q000494:pharmacology / Q000627:therapeutic use; D003165:Complement System Proteins / Q000276:immunology* / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D008024:Ligands; D015394:Molecular Structure; D019151:Peptide Library; D021281:Quantitative Structure-Activity Relationship; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D001685:Biological Factors; D008024:Ligands; D019151:Peptide Library; D011994:Recombinant Proteins; D003165:Complement System Proteins